<DOC>
	<DOCNO>NCT01697020</DOCNO>
	<brief_summary>The primary objective study determine whether test product , mercaptopurine oral 100 mg/5 mL suspension , reference product , PurinetholÂ® 50 mg tablet bioequivalent . For purpose PK profile 6-mercaptopurine ( 6-MP ) compare administration single dose two formulation , fast condition . The secondary objective ass safety tolerability test product , mercaptopurine oral 100 mg/5 mL suspension .</brief_summary>
	<brief_title>Bioequivalence An Oral Mercaptopurine Suspension 100 Mg / 5 Ml Versus Tablet Healthy Male Subjects Under Fasting Conditions</brief_title>
	<detailed_description />
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<criteria>Healthy male subject , 18 year 50 year inclusive time last administration IMP . Body Mass Index ( BMI ) 18.5 30 kg/m2 . Body mass le 50 kg . Medical history , physical examination , standard 12lead electrocardiogram ( ECG ) laboratory investigation : Findings clinically acceptable within laboratory reference range relevant laboratory test , unless investigator considers deviation irrelevant purpose study . Nonsmokers . Current alcohol use &gt; 21 unit alcohol per week male . Regular exposure substance abuse ( alcohol ) within past year . Use medication , prescribe overthecounter herbal remedy , within 2 week prior first administration IMP except affect outcome study opinion investigator . Participation another study experimental drug , last administration previous IMP within 8 week first administration IMP study . Treatment within previous 3 month first administration IMP drug welldefined potential adversely affect major organ system . A major illness 3 month commencement screening period . Subjects deficient , low intermediate TPMT enzyme activity mean phenotyping . Subjects participate previous azathioprine/mercaptopurine study within six month exclude . Relevant history laboratory clinical finding indicative acute chronic disease , likely influence study outcome . Donation loss blood equal exceed 500 mL 8 week first administration IMP . Diagnosis hypotension hypertension make screening period current diagnosis hypertension . Resting pulse &gt; 100 beat per minute &lt; 45 beat per minute screening period , either supine standing . Positive test HIV and/or Hepatitis B and/or Hepatitis C. Positive urine screen drug abuse . Positive urine screen tobacco use . Subjects plan procreate within 12 week IMP administration , willing practice reliable form contraception study least 12 week last dose IMP . Immunization use live organism vaccine within 4 week prior first dose IMP . Any specific IMP safety concern .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>